These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 21504319)
1. Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer. Fujiwara T; Shirakawa Y; Kagawa S Expert Rev Anticancer Ther; 2011 Apr; 11(4):525-32. PubMed ID: 21504319 [TBL] [Abstract][Full Text] [Related]
2. In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy. Kojima T; Watanabe Y; Hashimoto Y; Kuroda S; Yamasaki Y; Yano S; Ouchi M; Tazawa H; Uno F; Kagawa S; Kyo S; Mizuguchi H; Urata Y; Tanaka N; Fujiwara T Ann Surg; 2010 Jun; 251(6):1079-86. PubMed ID: 20485131 [TBL] [Abstract][Full Text] [Related]
3. A novel molecular therapy using bioengineered adenovirus for human gastrointestinal cancer. Fujiwara T Acta Med Okayama; 2011 Jun; 65(3):151-62. PubMed ID: 21709712 [TBL] [Abstract][Full Text] [Related]
4. [Theranostic application of telomerase-specific oncolytic adenovirus for human cancer]. Fujiwara T; Tanaka N Nihon Rinsho; 2007 Oct; 65(10):1913-22. PubMed ID: 17926546 [TBL] [Abstract][Full Text] [Related]
5. [Oncolytic virotherapy for human solid tumors]. Fujiwara T Gan To Kagaku Ryoho; 2009 May; 36(5):703-9. PubMed ID: 19461167 [TBL] [Abstract][Full Text] [Related]
6. Telomerase-specific virotheranostics for human head and neck cancer. Kurihara Y; Watanabe Y; Onimatsu H; Kojima T; Shirota T; Hatori M; Liu D; Kyo S; Mizuguchi H; Urata Y; Shintani S; Fujiwara T Clin Cancer Res; 2009 Apr; 15(7):2335-43. PubMed ID: 19318473 [TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer. Fujiwara T; Kagawa S; Tazawa H Curr Pharm Biotechnol; 2012 Jul; 13(9):1809-16. PubMed ID: 21740362 [TBL] [Abstract][Full Text] [Related]
8. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Fujiwara T; Urata Y; Tanaka N Curr Cancer Drug Targets; 2007 Mar; 7(2):191-201. PubMed ID: 17346111 [TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents. Fujiwara T; Urata Y; Tanaka N Front Biosci; 2008 Jan; 13():1881-6. PubMed ID: 17981675 [TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells. Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma. Liu L; Wu W; Zhu G; Liu L; Guan G; Li X; Jin N; Chi B Int J Mol Med; 2012 Oct; 30(4):747-54. PubMed ID: 22842823 [TBL] [Abstract][Full Text] [Related]
13. Enhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequences. Sugio K; Sakurai F; Katayama K; Tashiro K; Matsui H; Kawabata K; Kawase A; Iwaki M; Hayakawa T; Fujiwara T; Mizuguchi H Clin Cancer Res; 2011 May; 17(9):2807-18. PubMed ID: 21346145 [TBL] [Abstract][Full Text] [Related]
14. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA. Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241 [TBL] [Abstract][Full Text] [Related]
15. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145 [TBL] [Abstract][Full Text] [Related]
16. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667 [TBL] [Abstract][Full Text] [Related]
17. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Bilsland AE; Merron A; Vassaux G; Keith WN Cancer Res; 2007 Feb; 67(3):1299-307. PubMed ID: 17283167 [TBL] [Abstract][Full Text] [Related]
18. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958 [TBL] [Abstract][Full Text] [Related]
19. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Fujiwara T; Tanaka N Uirusu; 2008 Jun; 58(1):11-8. PubMed ID: 19122384 [TBL] [Abstract][Full Text] [Related]
20. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]